The nation’s first new guidelines in a decade for preventing heart attacks and strokes call for twice as many Americans – one-third of all adults – to consider taking cholesterol-lowering statin drugs.
The guidelines, issued Tuesday by the American Heart Association and American College of Cardiology, are a big change. They offer doctors a new formula for estimating a patient’s risk that includes many factors in addition to a high cholesterol level, the main focus now. The formula includes age, gender, race and factors such as whether someone smokes.
The guidelines for the first time take aim at strokes, not just heart attacks. Partly because of that, they set a lower threshold for using medicines to reduce risk.
The definition of high cholesterol isn’t changing, but the treatment goal is. Instead of aiming for a specific number, using whatever drugs get a patient there, the advice stresses statins such as Lipitor and Zocor and identifies four groups of people they help the most.
“The emphasis is to try to treat more appropriately,” said Dr. Neil Stone, the Northwestern University doctor who headed the cholesterol guideline panel. “We’re going to give statins to those who are the most likely to benefit.”
Doctors say the new approach will limit how many people with low heart risks are put on statins simply because of a cholesterol number. Yet under the new advice, one-third of U.S. adults – 44 percent of men and 22 percent of women – would meet the threshold to consider taking a statin. Under the current guidelines, statins are recommended for only about 15 percent of adults.
Some doctors not involved in writing the guidance worry that it will be tough to understand.
“It will be controversial, there’s no question about it. For as long as I remember, we’ve told physicians and patients we should treat their cholesterol to certain goal levels,” said the Cleveland Clinic’s Dr. Steven Nissen. “There is concern that there will be a lot of confusion about what to do.”
The government’s National Heart, Lung and Blood Institute appointed expert panels to write the new guidelines in 2008, but in June said it would leave drafting them to the Heart Association and College of Cardiology. New guidelines on lifestyle and obesity also came out Tuesday, and ones on blood pressure are coming soon.
Roughly half the cholesterol panel members have financial ties to makers of heart drugs, but panel leaders said no one with industry connections could vote on the recommendations.
“It is practically impossible to find a large group of outside experts in the field who have no relationships to industry,” said Dr. George Mensah of the heart institute. He called the guidelines “a very important step forward” based on solid evidence, and said the public should trust them.
Heart disease is the leading cause of death worldwide. High cholesterol leads to hardened arteries that can cause a heart attack or stroke. Most cholesterol is made by the liver, so diet changes have a limited effect on it.
Millions of Americans take statins, which reduce cholesterol dramatically and have other effects that more broadly lower the chances of heart trouble.
The patents on Lipitor, Zocor and other statins have expired, and they are widely available in generic versions for as little as a dime a day. One that is still under patent protection is AstraZeneca’s Crestor, which had sales of $8.3 billion in 2012.
Despite a small increased risk of muscle problems and accelerating diabetes in patients already at risk for it, statins are “remarkably safe drugs” whose benefits outweigh their risks, said Dr. Donald Lloyd-Jones, preventive-medicine chief at Northwestern.
Current guidelines say total cholesterol should be under 200, and LDL, or “bad cholesterol,” under 100. Other drugs such as niacin and fibrates are sometimes added to statins to try to reach those goals, but studies show they don’t always lower the chances of heart problems.
“Chasing numbers can lead us to using drugs that haven’t been proven to help patients. You can make someone’s lab test look better without making them better,” said Yale University cardiologist Dr. Harlan Krumholz, who has long urged the broader risk approach the new guidelines take.
They say statins do the most good for:
• People who already have heart disease.
• Those with LDL of 190 or higher, usually because of genetic risk.
• People ages 40 to 75 with Type 2 diabetes.
• People ages 40 to 75 who have an estimated 10-year risk of heart disease of 7.5 percent or higher, based on the new formula. (This means that for every 100 people with a similar risk profile, seven or eight would have a heart attack or stroke within 10 years.)
Aspirin – widely used to lower the risk of strokes and heart attacks – is not addressed in the guidelines. And many drugs other than statins are still recommended for certain people, such as those with high triglycerides.
Patients should not stop taking any heart drug without first checking with their doctor.
The American Heart Association and American College of Cardiology have issued the first new guidelines in a decade for preventing heart attacks and strokes. Among other things, they call for twice as many Americans – one-third of all adults – to consider taking cholesterol-lowering statin drugs.
The guidelines take aim at strokes, not just heart attacks. They’re personalized for men and women, and blacks and whites. They estimate a person’s risk in a novel way and change the goal of treating high cholesterol.
A new formula includes age, sex, race, blood pressure, cholesterol, diabetes and smoking. People ages 40 to 79 should get an estimate every four to six years. If risk is still unclear, family history or three other tests can be considered. The best one is a coronary artery calcium test.
High cholesterol leads to hardened arteries, which can cause a heart attack or stroke. Many people need medicines to lower their risk. The guidelines don’t change the definition of high cholesterol, but they say doctors should no longer aim for a specific number with whatever drugs can get a patient there. The new advice stresses statins such as Lipitor and Zocor.
THE BOTTOM LINE
About one-third of U.S. adults – 44 percent of men and 22 percent of women – would have enough risk to consider a statin. Only 15 percent of adults do now.
© Copyright Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.